What is Novaerus?
Novaerus is at the forefront of combating indoor air quality issues, including the mitigation of airborne viruses, bacteria, and allergens. Their proprietary NanoStrike technology is engineered for continuous air disinfection and particle reduction, making their solutions indispensable for environments demanding stringent infection control, such as hospitals, educational institutions, and dental clinics. The company offers a range of portable and accessible air disinfection devices, including the Defend 400 and Defend 1050 models, designed to bolster safety and maintain optimal air purity in diverse settings.
How much funding has Novaerus raised?
Novaerus has raised a total of $10M across 1 funding round:
Private Equity
$10M
Private Equity (2014): $10M with participation from Polaris Partners
Key Investors in Novaerus
Polaris Partners
Polaris Partners is a venture capital firm that specializes in backing transformational companies in the biotech and healthcare sectors. They partner with entrepreneurs to create successful business solutions, providing coaching, advice, and resources for growth.
What's next for Novaerus?
The substantial enterprise-level funding secured by Novaerus signals a strong trajectory for scaling its operations and further innovating its air purification technologies. This capital infusion is expected to accelerate market penetration, particularly within the healthcare and education sectors, where the demand for advanced air disinfection solutions is paramount. Novaerus is strategically positioned to expand its reach, enhance its product development pipeline, and solidify its leadership in providing safe and healthy indoor air environments.
See full Novaerus company page
